药物对比
Semaglutide vs Repaglinide
Semaglutide与Repaglinide治疗2型糖尿病对比：GLP-1受体激动剂与格列奈类。比较A1c、减重、心血管获益与餐后血糖控制及低血糖风险。
此页面暂无可用的对比维度。
临床背景
This comparison is relevant when choosing oral agents for type 2 diabetes, especially oral GLP-1 (Rybelsus) versus a mealtime meglitinide in patients needing postprandial coverage.
结论
Semaglutide is generally preferred for broader metabolic and CV benefits, while Repaglinide suits flexible mealtime dosing with functioning beta cells.
全部药物对比